Dilafor AB
http://www.dilafor.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Dilafor AB
Pipeline Watch: Phase III Starts In MS, Hyperkalemia And Short Stature
Pipeline Watch has been updated to bring greater depth and detail to a potential therapeutic product’s progress through the R&D pipeline. The table brings you a snapshot of selected late-stage clinical trial events in the pharma and biotech industries.
Deals Shaping The Medical Industry, June 2014
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced April through May 2014.
Deals Shaping The Medical Industry, April 2014
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced February through March 2014.
Lee's picks up China rights to Dilafor's tafoxiparin
Lee's Pharmaceutical Holdings has added to its list of licensing partners through an agreement with the private Swedish drug development firm Dilafor for Chinese rights to tafoxiparin.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice